Bcl-2 phosphorylation has pathological significance in human breast cancer

被引:12
作者
Matsuyoshi, Syuichi [1 ]
Shimada, Keiji [1 ]
Nakamura, Mitsutoshi [1 ]
Ishida, Eiwa [1 ]
Konishi, Noboru [1 ]
机构
[1] Nara Med Univ, Sch Med, Dept Pathol, Kashihara, Nara 6348521, Japan
关键词
bcl-2; phosphorylation; breast cancer; immunohistochemistry;
D O I
10.1159/000096022
中图分类号
Q2 [细胞生物学];
学科分类号
071009 [细胞生物学]; 090102 [作物遗传育种];
摘要
The anti-apoptotic molecule, Bcl-2, is well known to play an important role in the chemoresistance of breast cancer. We have previously demonstrated that phosphorylation of Fasassociated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel. In this study, the clink copathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens. Expression of P-Bcl-2 was found to significantly correlate with lymphatic invasion, lymph node metastasis, but not histological differentiation, tumor grade or vascular and fatty invasion. The positivity of P-Bcl-2 was also significantly correlated to that of P-FADD/JNK. Thus, PBcl-2 as well as the P-FADD/JNK parameter might be useful markers for cancer progression, independent of the hormone receptor status, in human breast cancers. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:205 / 212
页数:8
相关论文
共 39 条
[1]
Cell cycle effects by C-FADD depend on its C-terminal phosphorylation site [J].
Alappat, EC ;
Volkland, J ;
Peter, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (43) :41585-41588
[2]
MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance [J].
Atanaskova, N ;
Keshamouni, VG ;
Krueger, JS ;
Schwartz, JA ;
Miller, F ;
Reddy, KB .
ONCOGENE, 2002, 21 (25) :4000-4008
[3]
Berardo MD, 1998, CANCER, V82, P1296, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1296::AID-CNCR12>3.0.CO
[4]
2-1
[5]
BHARGAVA V, 1994, AM J PATHOL, V145, P535
[6]
Blagosklonny MV, 1996, CANCER RES, V56, P1851
[7]
FADD, A NOVEL DEATH DOMAIN-CONTAINING PROTEIN, INTERACTS WITH THE DEATH DOMAIN OF FAS AND INITIATES APOPTOSIS [J].
CHINNAIYAN, AM ;
OROURKE, K ;
TEWARI, M ;
DIXIT, VM .
CELL, 1995, 81 (04) :505-512
[8]
Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer [J].
Chung, YL ;
Sheu, ML ;
Yang, SC ;
Lin, CH ;
Yen, SH .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (03) :306-312
[9]
Prognostic and predictive value of p53 and p21 in breast cancer [J].
Elledge, RM ;
Allred, DC .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) :79-98
[10]
Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation [J].
Furukawa, Y ;
Iwase, S ;
Kikuchi, J ;
Terui, Y ;
Nakamura, M ;
Yamada, H ;
Kano, Y ;
Matsuda, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (28) :21661-21667